Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas

Cancer

Volumn 115, Issue 1, 2009, Pages 107-118

  Dobashi, Yoh ^a   Suzuki, Shioto ^b   Matsubara, Hirochika ^c   Kimura, Maiko ^a   Endo, Shunsuke ^a   Ooi, Akishi ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Epidermal growth factor receptor; Lung carcinomas; Mammalian target of rapamycin; Metastasis; Morphogenesis; Phosphorylation; Rapamycin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOPROTEIN; PROTEIN KINASE B; S6 KINASE;

ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR DIFFERENTIATION; DISEASE ASSOCIATION; DOWN REGULATION; EGFR GENE; SIGNAL TRANSDUCTION; SQUAMOUS CELL LUNG CARCINOMA; UPREGULATION;

ADENOCARCINOMA; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASMS, SQUAMOUS CELL; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION;

EID: 58949095529     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23996     Document Type: Article

References (36)

1. Blackhall FH, Shepherd FA, Albain KS. Improving survival and reducing toxicity with chemotherapy in advanced nonsmall cell lung cancer: a realistic goal? Treat Respir Med. 2005;4:71-84.
2. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169-181.
3. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science. 2006;312:1175-1178.
4. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807.
5. Suzuki S, Dobashi Y, Sakurai H, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer. 2005;103:1265-1273.
6. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163-1167.
7. Suzuki S, Igarashi S, Hanawa M, et al. Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. Mod Pathol. 2006;19:986-998.
8. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene. 2006;25:6416-6422.
9. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471-484.
10. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006;94:195-199.
11. Fingar DC, Richardson CJ, Tee AR, et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004;24:200-216.
12. Shaw RJ, Cantley LC. Ras, PIK and mTOR signalling controls tumour cell growth. Nature. 2006;441:424-430.
13. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006;66:10040-10047.
14. Milton DT, Riely GJ, Azzoli CG, et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer. 2007;110:599-605.
15. Papadimitrakopoulou V, Adjei AA. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. J Thorac Oncol. 2006;1:749-751.
16. Travis WD, Colby TV, Corrin B, et al, eds. The World Health Organization Histological Typing of Lung and Pleural Tumours. 3rd ed. New York, NY: Springer-Verlag; 1999.
17. [No authors listed] The World Health Organization histological typing of lung tumours. Second edition. Am J Clin Pathol. 1982;77:123-136.
18. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
19. Ikeda S, Takabe K, Inagaki M, et al. Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas. Pathol Int. 2007;57:268-275.
20. Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res. 2006;66:5618-5623.
21. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 2004;25:2053-2059.
22. Dobashi Y, Suzuki S, Sugawara H, Ooi A. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors. Hum Pathol. 2007;38:914-925.
23. Wu F, Liu SY, Tao YM, et al. Decreased expression of methyl methansulfonate and ultraviolet-sensitive gene clone 81 (Mus81) is correlated with a poor prognosis in patients with hepatocellular carcinoma. Cancer. 2008;112:2002-2010.
24. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999;18:813-822.
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
26. Chow S, Minden MD, Hedley DW. Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp Hematol. 2006;34:1183-1191.
27. Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem. 2005;280:25485-25490.
28. Lee CH, Inoki K, Karbowniczek M, et al. Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J. 2007;26:4812-4823.
29. Kim JE, Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin- associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci USA. 2000;97:14340-14345.
30. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006;66:6589-6597.
31. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122-1128.
32. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296-1302.
33. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500-1508.
34. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006;66:10100-10111.
35. Toral-Barza L, Zhang WG, Huang X, et al. Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines. Mol Cancer Ther. 2007;6:3028-3038.
36. Papa V, Tazzari PL, Chiarini F, et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia. 2008;22:147-160.